维格列汀联合阿卡波糖治疗2型糖尿病的疗效及安全性分析

Analysis of the Efficacy and Safety of Vildagliptin Combined with Acarbose in the Treatment of Type 2 Diabetes

目的研讨2型糖尿病应用维格列汀和阿卡波糖共同医治的效果和用药安全性。方法选择该院2017年3月—2018年9月期间86例2型糖尿病患者,按医治方法不同分成两组,阿卡波糖组和联合组,各43例。阿卡波糖组给予阿卡波糖治疗,联合组给予阿卡波糖和维格列汀共同治疗,观察两组医治前后空腹血糖(FPG)、糖化血红蛋白(Hb A1c)、餐后2 h血糖(2 h PG)、体重指数(BMI)的变化和医治效果以及用药不良反应发生情况。结果医治前两组FPG、Hb A1c、2 h PG、BMI相比差异无统计学意义(P>0.05),医治后联合组的FPG、Hb A1c、2 h PG均小于阿卡波糖组,差异有统计学意义(P<0.05),BMI相比差异无统计学意义(P>0.05);两组医治效果相比中,联合组总有效率为95.35%,显著比阿卡波糖组的81.40%高,差异有统计学意义(P<0.05);两组用药不良反应发生率都较低,且相比差异无统计学意义(P>0.05)。结论 2型糖尿病应用维格列汀和阿卡波糖共同医治能改善糖代谢,提高医治效果,且用药安全性高。

Objective To study the efficacy and safety of the combined treatment of vildagliptin and acarbose for type 2 diabetes.Methods Eighty-six patients with type 2 diabetes were selected from the hospital from March 2017 to September 2018.They were divided into two groups according to different treatment methods,the acarbose group and the combined group,with 43 cases in each group.The acarbose group was treated with acarbose,and the combination group was treated with acarbose and vildagliptin.The fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c),and two hours postprandial blood glucose(2 hPG),changes in body mass index(BMI),treatment effects,and adverse reaction of medication.Results There was not statistically significant difference in FPG,HbA1c,2 hPG,and BMI between the two groups before treatment(P>0.05).After treatment,the FPG,HbA1c,and 2 hPG of the combined group were all lower than those in the acarbose group,the difference was statistically significant(P<0.05),and there was not statistically significant difference in BMI(P>0.05);Compared the treatment effects between the two groups,the total effective rate of the combined group was 95.35%,which was significantly higher than 81.40%of the acarbose group,the difference was statistically significant(P<0.05);the incidence of adverse reaction was lower in both groups,and there was not statistically significant difference in comparison(P>0.05).Conclusion The combined treatment of vildagliptin and acarbose for type 2 diabetes can improve glucose metabolism,improve the treatment effect,and have high drug safety.